Versant Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Versant Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.09K	Sell	450 -196	-30%	-$3.71K	﹤0.01%	2293
2026 Q1	$14.1K	Buy	646 +24	+4%	+$465	﹤0.01%	1986
2025 Q4	$13.4K	Buy	+622	New	+$13.1K	﹤0.01%	1866
2025 Q3	–	Sell	-108	Closed	-$1.85K	–	2717
2025 Q2	$1.85K	Buy	+108	New	+$4.61K	﹤0.01%	2399
2025 Q1	–	Sell	-23	Closed	-$2.8K	–	2615
2024 Q4	$2.8K	Sell	23 -25	-52%	-$3.06K	﹤0.01%	1974
2024 Q3	$6K	Sell	48 -15	-24%	-$2.07K	﹤0.01%	1232
2024 Q2	$9.95K	Buy	+63	New	+$8.09K	﹤0.01%	994
2023 Q3	–	Sell	-1	Closed	-$115	–	2047
2023 Q2	$115	Buy	+1	New	+$129	﹤0.01%	2027
2022 Q1	–	Sell	-7	Closed	-$1K	–	1617
2021 Q4	$1K	Sell	7 -4	-36%	-$342	﹤0.01%	1349
2021 Q3	$1K	Sell	11 -35	-76%	-$2.7K	﹤0.01%	1369
2021 Q2	$4K	Buy	46 +37	+411%	+$2.81K	﹤0.01%	983
2021 Q1	$1K	Buy	+9	New	+$830	﹤0.01%	1435

Other funds holding SRPT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Versant Capital Management's SRPT Position: Q2 2026 in Review

Versant Capital Management reduced its Sarepta Therapeutics (SRPT) stake by 30% in Q2 2026, selling an estimated $3.71K and leaving 450 shares worth $8.09K. The position accounts for ﹤0.01% of the portfolio, ranked #2293.

Versant Capital Management first reported a position in SRPT in Q1 2021 and has held it in 12 quarters since. The position peaked at $14.1K in Q1 2026. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

Versant Capital Management held 450 shares of Sarepta Therapeutics worth $8.09K as of Q2 2026.
Versant Capital Management sold 196 Sarepta Therapeutics shares in Q2 2026, an estimated $3.71K.
Sarepta Therapeutics made up ﹤0.01% of Versant Capital Management's portfolio in Q2 2026, its #2293 holding.
Versant Capital Management first reported a position in Sarepta Therapeutics in Q1 2021 and has held it in 12 quarters since.
Versant Capital Management's Sarepta Therapeutics position peaked at $14.1K in Q1 2026.
323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Versant Capital Management's 13F filing for Q2 2026, filed 2 Jul 2026.